Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan

Link to article at PubMed

Ann Pharmacother. 2020 Oct 28:1060028020964923. doi: 10.1177/1060028020964923. Online ahead of print.


Heart failure is a major public health concern with a rising prevalence and significant financial detriment. Although sacubitril/valsartan was shown to reduce the risk of death and hospitalization from heart failure in a contemporary cohort, it continues to remain substantially underutilized. A recent article in the Annals highlights the evidence behind inpatient initiation of sacubitril/valsartan. We provide further considerations and summarize the evidence for inpatient initiation of other guideline directed medical therapies. Overall, there is a need to improve methods to identify ideal populations and increase utilization in those who may benefit from sacubitril/valsartan. Further research is also needed to identify the risks versus benefits among underrepresented populations (i.e., advanced heart failure, heart failure with preserved ejection fraction, in conjunction with other contemporary evidence-based therapies that can lower blood pressure, etc.).

PMID:33111533 | DOI:10.1177/1060028020964923

Leave a Reply

Your email address will not be published. Required fields are marked *